Brookline Capital Initiates Coverage On iBio with Buy Rating, Announces Price Target of $3.6
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has initiated coverage on iBio (AMEX:IBIO) with a Buy rating and set a price target of $3.6.

July 22, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Brookline Capital has initiated coverage on iBio with a Buy rating and set a price target of $3.6.
The initiation of coverage with a Buy rating and a specific price target of $3.6 by Brookline Capital is likely to positively impact iBio's stock price in the short term. Such analyst ratings often lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100